Valsts: Lielbritānija
Valoda: angļu
Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)
Canine adenovirus, Canine coronovirus, Canine distemper virus, Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae
Pfizer Ltd
QI07AJ(a
Canine adenovirus, Canine coronovirus, Canine distemper virus, Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrh
Expired
Revised: October 2010 AN: 01713/2009 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCT Duramune DAP + LC 2. QUALITATIVE AND QUANTITATIVE COMPOSITION QUALITATIVE COMPOSITION Combined canine distemper virus vaccine (live), freeze dried; canine adenovirus vaccine (live), freeze dried; canine parvovirosis vaccine (live), freeze dried, canine leptospirosis vaccine (inactivated) and canine coronavirus vaccine (inactivated). QUANTITATIVE COMPOSITION 1. FREEZE-DRIED FRACTION: Active Substances Per 1 ml dose Canine Distemper virus, strain Onderstepoort 10 2.5 to 10 4.8 TCID 50 * Canine Adenovirus type 2, strain V197 10 4.8 to 10 7.0 TCID 50 * Canine Parvovirus, strain SAH 10 4.7 to 10 6.5 TCID 50 * *TCID50 = tissue culture 50% infective dose Excipients None giving rise to safety concerns. For a full list of excipients, see section 6.1. 2. LIQUID DILUENT FRACTION: Active Substances Per 1 ml dose Inactivated _Leptospira interrogans _bacteria (outer membrane coat) Serogroup _canicola_, Serovar _canicola _ Potency according to Ph.Eur.* Serogroup _icterohaemorrhagiae_, serovar _Icterohaemorrhagiae_ Potency according to Ph.Eur.* Canine coronavirus, strain TN449 (inactivated) RP** 1.0-2.0 Adjuvants Ethylene/Maleic anhydride (EMA) 0.01 ml Neocryl A640 0.03 ml Page 1 of 6 Revised: October 2010 AN: 01713/2009 Excipients None giving rise to safety concerns. For a full list of excipients, see section 6.1. * hamster 80% protective dose according to Ph.Eur. ** RP = Relative Potency 3. PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the active immunisation of dogs to prevent mortality and disease caused by canine distemper virus and canine Izlasiet visu dokumentu